Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Emerald Health Therapeutics Inc TBQBF


Primary Symbol: EMHTF

Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products with an emphasis on innovation and production excellence.


OTCQB:EMHTF - Post by User

Post by VENManon Mar 28, 2019 10:07pm
126 Views
Post# 29551850

TBV

TBVAlso, when you consider tangible book value for EMH it's much lower than book value because they have a huge intangible asset of $87M on the books. So the book value of $1.26 per share would be reduced by intangible book value to get Tangible Book Value which is currently 63 cents. At $4 per share the market is paying 6.35 times TBV. Now if you add $39M to assets it increases the common stock but taking that into account the TBV would increase from 63 cents to 89 cents and if the market was still willing to pay PTBV of 6.35 times then Tangible Book Value .89 X 6.35 PTBV = $5.65 per share. 
So although you're adding 10 common stock to the float you're also increasing assets, cash in this case by $39M which has an overall positive impact on Book Value.
The worse thing EMH could do is get that $39M and go spend it on some stupid pharma company adding it all to an already high intangible asset of $87M. 
The intangible assets as a percentage of total assets seems way to high here for a start up and adding cash would reduce that intangible asset percentage over total assets so this is good news for me as i see it.
All imo!   




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse